Log in
Sign up
Golden has been acquired by ComplyAdvantage.Read about it here ⟶
‌

US Patent 11767359 C3-binding agents and methods of use thereof

Patent 11767359 was granted and assigned to NGM Biopharmaceuticals on September, 2023 by the United States Patent and Trademark Office.

OverviewStructured DataIssuesContributorsActivity
Is a
Patent
Patent
Current Assignee
NGM Biopharmaceuticals
NGM Biopharmaceuticals
Date Filed
August 19, 2021
Date of Patent
September 26, 2023
Patent Applicant
NGM Biopharmaceuticals
NGM Biopharmaceuticals
Patent Application Number
17406991
Patent Citations
‌
US Patent 9291622 Complement assays and uses thereof
‌
US Patent 11136381 Anti-C3 antibodies
‌
US Patent 9745367 Alternative pathway specific antibodies for treating arthritis
‌
US Patent 7816497 Compositions and methods for inhibiting drusen complement components C3a and C5a for the treatment of age-related macular degeneration
‌
US Patent 8012473 C3b antibodies and methods for the prevention and treatment of complement-associated disorders
‌
US Patent 8168584 Methods of treating age-related macular degeneration by compstatin and analogs thereof
‌
US Patent 8192742 Method of inhibiting complement activation with human anti-factor C3 antibodies and use thereof
‌
US Patent 8377437 C3b antibodies and methods for the prevention and treatment of complement-associated disorders
Patent Inventor Names
Zhonghao Liu
Jared Martin Higbee
Wenwu Zhai
Yiyuan Yin
Jie Tang
Yan Wang
Dana Yen Mei Duey
Patent Jurisdiction
United States Patent and Trademark Office
United States Patent and Trademark Office
Patent Number
11767359
Patent Primary Examiner
‌
Michael Szperka

Find more entities like US Patent 11767359 C3-binding agents and methods of use thereof

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
Open Query Tool
Access by API
Golden Query Tool
Golden logo
By using this site, you agree to our Terms of Service.